TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04397744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unidas por Vida y Salud prevention program
Description: The Unidas por Vida y Salud (United for Life and Health) prevention program is led by the El Paso Cancer and Chronic Disease Consortium (CCDC), the only Breast and Cervical Cancer Services (BCCS) provider in El Paso. This prevention program will use a well-integrated network of community organizations and health service providers to connect medically underserved women to services. To reach the most underserved women and increase preventive cancer screening and timely follow-up, diagnosis, and treatment, the multi-method approach uses evidence-based strategies, including face-to-face educational sessions led by promotoras (community health workers), client reminders, and provision of community-based navigation services to affordable and free screening services. The program also includes clinic-based navigation for those requiring diagnostics or treatment delivered by trained nurses and case workers.
Study: NCT01578655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cabazitaxel
Description: Cabazitaxel (25mg/m² IV) is administered on day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Description: Cabazitaxel (25mg/m² IV) is administered on day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Prednisone (10 mg PO) is administered daily until disease progression, unacceptable toxicity, or completion of 10 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Prednisone (10 mg PO) is administered daily until disease progression, unacceptable toxicity, or completion of 10 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: custirsen sodium
Description: Custirsen is administered as 3 loading doses (640 mg IV each) within 9 days, followed by weekly custirsen (640 mg IV) during each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
Study: NCT00950313

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self Assessment
Description: Self assessment used to determine current risk of diabetes and likelihood of requiring further testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic risk score
Description: Patients current risk of diabetes is determined by a electronic risk algorithm. They are then invited to attend fof further testing.
Study: NCT00473031

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Participants will be asked to attend eight 50-minute diet counseling sessions, with the opportunity to attend a total of approximately 28 diet counseling sessions, during the year.
Study: NCT03000855

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided choledocho-duodenostomy
Description: The CBD would be identified by a linear echoendoscope and a suitable puncture site in the bulb of the duodenum would be located. The common bile duct would be punctured with a 19-gauge needle and the position would be confirmed by aspiration of bile and contrast injection. A 0.025 or 0.035 guide wire would be passed through the needle in to the CBD. A fully covered metal stent would then be inserted after track dilation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography with covered metallic stent
Description: After cannulation of the CBD, a cholangiography would be performed to assess the diameter of the CBD, the length and position of the biliary stricture. The endoscopist would decide on the appropriate size of SEMS to be placed. The stents should be visible from the duodenal lumen after deployment.
Study: NCT01582139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart rate informed SSM+HMM
Description: The Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) of the Closed Loop is informed about heart rate during exercise. The goal is to demonstrate the feasibility of a modular insulin management system based on continuous glucose monitoring that additionally employs heart rate information to reduce exercise-related hypoglycemic episodes.
Study: NCT03202719

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent oral poliovirus vaccine (bOPV) at 6,10 and 14 weeks of age
Description: bOPV at 6, 10 and 14 weeks of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent oral poliovirus vaccine (bOPV) at 6,10 and 14 weeks of age
Description: bOPV at 6, 10 and 14 weeks of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age
Description: IPV at 14 weeks and 18 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age
Description: IPV at 14 weeks, 18 weeks and 18 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age
Description: IPV at 14 weeks and 9 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age
Description: IPV at 6 weeks and 9 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age
Description: IPV at 6 and 14 weeks of age
Study: NCT01103583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: 500 mg/die per os for two years

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 500 mg/die per os for two years
Study: NCT01330329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard behavioral treatment
Description: Participants receive a standard behavioral weight loss program similar to that used in other large trials such as Look AHEAD and the Diabetes Prevention Program. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBT + technology system (SBT+FIT)
Description: Participants will receive a standard behavioral weight loss program and will also be asked to use the Body Media FIT system as part of their weight loss intervention. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors. Participants in this group will also wear an armband that measures energy expenditure and they will log their food intake on the internet.
Study: NCT00829842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral hygiene
Description: oral hygiene with 0.12% chlorexidine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral hygiene placebo
Study: NCT05642520

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Oval section abutment of 2.9 mm
Description: The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 5.9 and 6.3 mm, a 2.9 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circular section abutment of 3.3 mm
Description: The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 6.4 and 7.1 mm, a 3.3 mm implant was placed. Implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland).
Study: NCT03461146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6548
Description: Oral tablet
Study: NCT01646281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vernakalant
Description: 10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flecainide
Description: 10-minute infusion of 2 mg/kg (maximal 150 mg)
Study: NCT03523767

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: S.typhi Injection
Description: 0.5 ml of S.typhi injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S.typhi Injection
Description: 0.5 ml of S.typhi injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Injection
Description: 0.5 ml of normal saline injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Normal Saline Injection
Description: 0.5 ml of normal saline injection
Study: NCT01851629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Locomotor Training
Description: Individuals are provided manual assistance for intense, task-specific stepping practice on a treadmill and overground.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Locomotor Training
Description: Individuals are provided manual assistance for intense, task-specific stepping practice on a treadmill and overground.

Intervention type: OTHER
Group type: OTHER
Intervention: Cross-Sectional Testing (No Intervention)
Description: Individuals with and without spinal cord injury will be evaluated to develop protocols within our laboratory to assess reflexes (spinal tract integrity), walking ability, and whether mirror images during walking enhance or disrupt motor responses during walking.
Study: NCT01965704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Pregnant women may receive a second dose of IV ondansetron if they have not delivered within 4 hours of receiving the IV study medication. 50% of the 90 mother/baby pairs will receive ondansetron; the baby will always get the same study medication as the mother.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All doses of placebo, whether IV or oral, will mimic the same volume as the ondansetron group to maintain the blind. Pregnant women may receive a second dose of IV placebo if they have not delivered within 4 hours of being given the IV study medication. 50% of the 90 mother/baby pairs will receive placebo; the baby will always receive the same study medication as the mother.
Study: NCT00687804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.5 mg ranibizumab administered by intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg ranibizumab administered by intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg ranibizumab administered by intravitreal injection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Laser photocoagulation treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Laser photocoagulation treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Laser photocoagulation treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham laser
Description: Sham to laser procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham to ranibizumab
Description: Sham to ranibizumab administered as an intravitreal injection.
Study: NCT02442440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anisodamine
Description: Anisodamine will be given first as bolus of 10 mg, followed by 0.1-0.5mg/kg/hr. The adjustment of pump infusion rate is largely at the discretion of treating physician, with the aim of improving microcirculation and limit the side effect to a minimum. For example, if serum lactate continues to elevate, the infusion rate can be increased. Discontinuation on severe side effect or recovery of shock (normalized lactate, weaned from vasopressor) or death.
Study: NCT02754726

Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab
Description: Nivolumab 240mg 240 mg as a 60 minute infusion on days 1, 15, 29 per 42 day cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Albumin-bound paclitaxel
Description: 125 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Paricalcitol
Description: 25 micrograms IV on days 1,4,8,12,15,18,22,26,29,32,36,39 (+/-1 day allowed for dosing per 42 day cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: 25 mg/m2 over 60 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: 1000 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
Study: NCT03887715

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus Nerve Stimulation (VNS)
Description: VNS is an implantable device that delivers stimulation to the vagal nerve.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vagus Nerve Stimulation (VNS)
Description: VNS is an implantable device that delivers stimulation to the vagal nerve.
Study: NCT00206336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate (drug)
Description: Topiramate 25 mg to 200 mg
Study: NCT00404352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 mL.
Study: NCT01705444

Intervention type: DEVICE
Group type: OTHER
Intervention: Foley Catheter and The Spanner Insertion
Description: A Foley catheter will be inserted for 3-5 days, then a voiding trail will be attempted by the patient himself without the catheter. Then, the Spanner will be inserted into the same patient for another 3-5 days and an evacuation trail will be attempted also by the patient after removal of the Spanner. Treatment Satisfaction Questionnaire (TSQ) will be applied by the same person to the patient twice, once after removal of the Foley catheter and the second after removal of the Spanner.
Study: NCT01781923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation program
Description: Subject plays for 30 minutes, 4 times per week, for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small group social skills training
Description: Meet once per week for duration of 40 weeks.
Study: NCT04497818

Intervention type: OTHER
Intervention: Cross Sectional study using scientifically validated psychometric Scales
Description: Cross Sectional study using scientifically validated psychometric Scales (FEAR OF COVID-19, a 5 item Likert Scale \& Modified Dental Anxiety 5 item Likert Scale).
Study: NCT01566552

Intervention type: DRUG
Group type: OTHER
Intervention: AMBISOME
Description: SINGLE DOSE AMBISOME FOR TREATMENT OF VISCERAL LEISHMANIASIS
Study: NCT02602002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02143713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix tablets administered orally
Study: NCT01477177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polar Wand carbon dioxide cryotherapy
Description: Patients with Barrett's esophagus dysplasia will be treated with the Polar Wand device at 0 month, 2 and 4 months,6 months (with four quadrant surveillance biopsies), 8 and 10 months (treatment as necessary), and, at 12 months for final surveillance with biopsies throughout entire initial Barrett's segment length.
Study: NCT04291885

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV infusion
Study: NCT01462409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESMed S9 with humidifier H5i and heated tube Climate Line
Description: At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Controlled heated humidification with heated tubing (Climate Line).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP without humidification
Description: At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Without any humidification.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP with heated humidification
Description: At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. With controlled heated humidification and standard tubing.
Study: NCT01683786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegintron + Riba
Description: Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800\~1400 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegintron + Riba
Description: Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800\~1400 mg/day
Study: NCT01023009

Intervention type: PROCEDURE
Intervention: vitrectomy
Study: NCT03054701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip specific resistance exercise
Description: Hip specific resistance exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knee specific resistance exercise
Description: Knee specific resistance exercise
Study: NCT01437839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Period I: 1 x 5 mg Commercial Image Tablet in fasting state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fed state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Period I: 1 x 5 mg Commercial Image Tablet in fed state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fasting state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)
Study: NCT02969252

Intervention type: DRUG
Group type: OTHER
Intervention: Rifamycin SV-MMX® 600
Study: NCT01068639

Intervention type: BEHAVIORAL
Intervention: No treatment given
Description: No treatment given to study participants, only behaviorial patterns with respect to treatment compliance is observed.
Study: NCT05214625

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire concerning artificial intelligence and its implementation in healthcare. GI patients and GI physicians will be provided with slightly different questionnaires.

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire concerning artificial intelligence and its implementation in healthcare. GI patients and GI physicians will be provided with slightly different questionnaires.
Study: NCT04090125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAS Intervention
Description: The PAS program will be initiated during the final usual care PT visits. The PAS content will be included within the last two routine PT visits (Sessions 1 and 2). Session 1 will emphasize the importance of PA in TKA recovery, work with participants to establish SMART goals regarding overall PA and provide community-based and other resources to support overall PA. Session 2 will include balance exercise content to improve joint loading symmetry and home exercises will be assigned. Then, PAS participants will receive a follow-up phone call after 4 weeks (to assist with activity progression and problem-solving) and an additional in-person visit after 8 weeks (to visually monitor exercise performance and re-assess proportional weight-bearing ability).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: This will include usual in-person post TKA PT followed by 2 additional contacts (Session 1 and 2) with the physical therapist. Session 1 (phone) will review recovery benchmarks, assessment of participants' daily activities and reminders about symptoms that should trigger contacting a medical professional. Session 2 (in-person) will involve physical performance tests and comparison to appropriate normative values.
Study: NCT01722578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate
Description: L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sterile water, 60 ml) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
Study: NCT00699816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immuncell-LC
Description: Activated T lymphocyte
Study: NCT00976053

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myocardial perfusion imaging
Description: Randomization assignment to one of SPECT or PET myocardial perfusion imaging

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myocardial perfusion imaging
Description: Randomization assignment to one of SPECT or PET myocardial perfusion imaging
Study: NCT04477239

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (behaviour)
Description: Placebo is composed of pregelatinized maize starch Ph.Eur. 97.5%; magnesium stearate Ph.Eur. 1.5%; micronized silica Ph.Eur. 0.5%; Micronized talc Ph.Eur. 0.5% (NOT containing preservatives, colorings, or gluten).
Study: NCT03266406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronidase
Description: 4ml of retrobulbar LA with addition of 15IU/ml hyaluronidase to 2% lidocaine